The discovery and development of HMG-CoA reductase inhibitors.
Open Access
- 1 November 1992
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 33 (11) , 1569-1582
- https://doi.org/10.1016/s0022-2275(20)41379-3
Abstract
No abstract availableThis publication has 102 references indexed in Scilit:
- SimvastatinDrugs, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnoverThe Journal of Pediatrics, 1988
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Mevalonolactone derivatives as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.CHEMICAL & PHARMACEUTICAL BULLETIN, 1980
- Reduction of Blood Cholesterol in ManCirculation, 1953